Trial Profile
Long-term safety study of denosumab in patients with giant cell tumor who have received on average 48 doses of medication
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Giant cell tumours
- Focus Adverse reactions
- 10 Feb 2016 New trial record